Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00124332
Status:
COMPLETED
Last Update Posted:
2009-04-20
First Post:
2005-07-26
Brief Title:
STRADIVARIUS Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Randomized Multicenter Double-Blind Placebo-Controlled Two-Arm Parallel Group Trial of Rimonabant 20-mg od for Inhibition of Atherosclerosis Progression Assessed by IVUS IntraVascular UltraSounds in Overweight Patients With Clustering Risk Factors
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if rimonabant 20 mg once daily od administered during 18-20 months will reduce progression of coronary atherosclerosis as assessed by intravascular ultrasound IVUS when administered on top of standard behavioral and pharmacological therapy given as needed in patients with abdominal obesity associated with current smoking andor metabolic syndrome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None